# Actinium Pharmaceuticals Announces Three ASH 2026 Abstracts Highlighting Iomab-ACT Clinical Results in CAR T-Cell Therapy and Sickle Cell Disease

- Source: PR Newswire M&A
- Published: 2026-11-04T14:11:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-announces-three-ash-2026-abstracts-highlighting-iomab-act-clinical-results-in-car-t-cell-therapy-and-sickle-cell-disease-302929345.html
- Canonical: https://groundlevelnews.com/story/actinium-pharmaceuticals-announces-three-ash-2026-abstracts-highlighti-a11045/

The three abstracts strengthen the clinical foundation for Iomab-ACT's development as a targeted conditioning platform for cellular and gene therapies across cancer and nonmalignant diseases Phase 1b/2 trial evaluates targeted immune conditioning with Iomab-ACT before standard commercial...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._